TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01746979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TH-302
Description: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (5 percent dextrose - D5W)
Description: TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT01492322

Intervention type: RADIATION
Intervention: TRODAT
Description: Smoker will receive a TRODAT injection
Study: NCT02885961

Intervention type: DRUG
Group type: OTHER
Intervention: Dabigatran
Description: Anti-coagulant
Study: NCT03840564

Intervention type: OTHER
Intervention: Point of care (POC)
Description: All the analyzes will be done in delocalized
Study: NCT03420911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT02771470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Microbial composition using probiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Microbiota modulation using placebo
Study: NCT02234492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Comparison of rosuvastatin to no rosuvastatin
Study: NCT02494661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Cart and Stress Management Videos
Description: Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Cart Video
Description: Healthy Cart Video: educational video on healthy food shopping
Study: NCT03637426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite
Description: The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser + nano-hydroxyapatite
Description: GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
Study: NCT02972892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Et Control Feature
Description: Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fresh Gas
Description: Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case.
Study: NCT01907256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inverted V incision
Description: It is a type of incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stair step incisions
Description: It is a type of incision
Study: NCT03650530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Family Talk Intervention
Description: The family meets two interventionists at six time points.
Study: NCT00866944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adecatumumab
Description: Adecatumumab,6-9mg/kg, every 14 days, 24 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adecatumumab and FOLFOX
Description: FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 4
Description: FOLFOX 4, every 14 days, 12 cycles
Study: NCT02290444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic Hormone
Description: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
Study: NCT04010552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALRINOX combination
Description: NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
Study: NCT00817518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4987655
Description: Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4987655
Description: Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
Study: NCT02274506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg by vein on Days -8 and -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 by vein on Days -6 to -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion
Description: T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
Study: NCT03096158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilatory Muscle Training (TREMVEN)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
Study: NCT01181674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle therapy
Description: diet and exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Standard glycemic care
Description: as informed by the current clinical practice guidelines
Study: NCT00666965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Study: NCT01364909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual practice
Description: These patients will not receive exercise early in their intensive care admission
Study: NCT01089075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: 20 mg po for 7 days (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 tablets po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets po
Study: NCT03824574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Mandibular Advancement Appliance
Description: Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
Study: NCT05770687

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Patients started on SGLT2 inhibitors after PCI for AMI
Study: NCT00299091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz capsules 200 mg and 600 mg
Description: Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
Study: NCT03720067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg to 320mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: 40mg to 320mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg to 320mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 6.25mg to 25mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: 6.25mg to 25mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 6.25mg to 25mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of rosuvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of rosuvastatin
Study: NCT01049789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMB - Combination Cognitive Behavioral Therapy and Medication Management
Description: Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU - Treatment as Usual
Description: Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48.
Study: NCT04450394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT01601093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose
Description: Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoperazone and Sulbactam Sodium (CFP/SUB)
Description: Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
Study: NCT00948389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
Study: NCT02389868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Study: NCT00708344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan - Hydrochlorothiazide
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
Study: NCT02885961

Intervention type: RADIATION
Group type: OTHER
Intervention: FDG PET scan
Description: Scan using PET combined with a high resolution CT scan (HRCT)
Study: NCT03096158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AERO)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Handgrip Training (ISO)
Description: Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
Study: NCT02204202

Intervention type: DRUG
Intervention: [18F]FDG
Description: 10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition

Intervention type: DRUG
Intervention: [18F]FDG
Description: 10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition

Intervention type: DRUG
Intervention: [18F]ISO-1
Description: 8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition

Intervention type: DRUG
Intervention: [18F]ISO-1
Description: 8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study: NCT03748056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted incentives
Description: Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nominal loyalty card discount and nutrition education
Description: All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nominal loyalty card discount and nutrition education
Description: All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
Study: NCT01308801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS + rehabilitation exercise
Description: 14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
Study: NCT03299712

Intervention type: DEVICE
Group type: OTHER
Intervention: ArteFill
Description: soft tissue filler
Study: NCT03514433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIP Patient Navigation Intervention
Description: The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
Study: NCT04114110

Intervention type: OTHER
Intervention: RTLS data
Description: data extraction from RTLS

Intervention type: OTHER
Intervention: RTLS data
Description: data extraction from RTLS
Study: NCT00251251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy plus ICD
Description: ICD vs CRT/ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy plus CRT/ICD
Description: ICD vs CRT/ICD
Study: NCT00752726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Weight loss treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study: NCT03888209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
Study: NCT02939768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Description: ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
Study: NCT04312425

Intervention type: PROCEDURE
Intervention: Modified rapid sequence induction
Description: Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.

Intervention type: PROCEDURE
Intervention: Classic rapid sequence induction
Description: In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
Study: NCT00585793

Intervention type: DRUG
Intervention: NRTI/NNRTI/ Kaletra
Description: Fixed dose and cild formulation Kaletra
Study: NCT01218048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
Study: NCT03084887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manuals and follow-up
Description: distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
Study: NCT01308801

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo rTMS+ rehabilitation exercise
Description: 14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
Study: NCT02026687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal